Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | HNF4A | P41235 | 4/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15714465 | 0.85 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL1786657 | 0.80 | POLB (0.62) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL1785215 | 0.80 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL7824616 | 0.80 | CA12 (0.57) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL7827503 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3140547 | 0.76 | ALDH1A1 (0.67) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL5323825 | 0.76 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3905064 | 0.76 | CA12 (0.60) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL31516833 | 0.76 | POLB (0.60) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL9688748 | 0.75 | HSD17B10 (0.64) | KDM4EALDH1A1HPGDHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027445-A | Transition metal organic compound co-doped conductive material and preparation method thereof | 陕西科技大学 | 2024-05-14 | — | — | CN | claimed |
| WO-2011040680-A2 | DYE-SENSITIZED/LIGAND-TO-METAL CHARGE-TRANSFER HYBRID SOLAR CELL COMPRISING A WORKING ELECTRODE INCLUDING NANO-OXIDE LAYER COMPOSED OF NANO-OXIDE PARTICLES ADSORBED WITH DYES AND LIGANDS AND METHOD OF MANUFACTURING THE SAME | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2011-04-07 | — | — | WO | claimed |
| CN-118027445-A | Transition metal organic compound co-doped conductive material and preparation method thereof | 陕西科技大学 | 2024-05-14 | — | — | CN | disclosed |
| US-20220220368-A1 | METHOD FOR PREPARING PHOTORESPONSIVE SELF-POWERED ELECTROCHROMIC PRECURSOR, METHOD FOR FABRICATING PHOTORESPONSIVE SELF-POWERED ELECTROCHROMIC DEVICE AND PHOTORESPONSIVE SELF-POWERED ELECTROCHROMIC DEVICE FABRICATED BY THE FABRICATION METHOD | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2022-07-14 | — | — | US | disclosed |
| US-10711027-B2 | DNA polymerase beta inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-07-04 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-101849953-B | Inflammatory cytokine release inhibitor | INST MED MOLECULAR DESIGN INC | 2012-04-25 | — | — | CN | disclosed |
| EP-1844766-B1 | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20020127577-A1 | Bioactive sensors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-09-12 | — | — | US | disclosed |
| EP-1185869-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | Graffinity Pharmaceutical Design GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000073796-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICAL DESIGN GMBH (DE) | 2000-12-07 | — | — | WO | disclosed |
| US-4654331-A | Oral absorption enhancement of carboxylic acid pharmaceuticals using (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl ester group | MERCK & CO., INC. (US) | 1987-03-31 | — | — | US | disclosed |
| US-4479947-A | Oral absorption enhancement of carboxylic acid pharmaceuticals using (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl ester group | MERCK & CO., INC. (US) | 1984-10-30 | — | — | US | disclosed |
| US-4391814-A | Derivatives of antiphlogistically effective carboxylic acids, their preparation and medicinal use | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-07-05 | — | — | US | disclosed |
| EP-0070013-A1 | Oral absorption enhancement of carboxylic acid pharmaceuticals using (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl ester group | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0054812-A1 | Derivatives of antiphlogistically active carboxylic acids, their preparation and medical application | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711027-B2 | DNA polymerase beta inhibitors | POLB, POLH, POLN | KDM4E 3702/4885ALDH1A1 908/4885HPGD 506/4885 |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | POLB, POLH, POLN | KDM4E 3702/4885ALDH1A1 908/4885HPGD 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.